Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2719121 | 0.88 | KDM4E (0.50) | SMN1; SMN2ALDH1A1KMT2AMEN1GAA | |
| SCHEMBL7613832 | 0.86 | HSP90AA1 (0.48) | SMN1; SMN2ALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL21518879 | 0.86 | HSD17B10 (0.43) | SMN1; SMN2ALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL19940202 | 0.85 | HSD17B10 (0.46) | SMN1; SMN2ALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL859758 | 0.85 | HSD17B10 (0.42) | SMN1; SMN2ALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL9295787 | 0.79 | HSD17B10 (0.42) | SMN1; SMN2ALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL31575 | 0.78 | KDM4E (0.58) | SMN1; SMN2ALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL29706037 | 0.77 | CDC7 (0.47) | ALDH1A1KMT2AMEN1HSD17B10GAA | |
| SCHEMBL3333926 | 0.77 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1HSD17B10GAA | |
| SCHEMBL2555611 | 0.77 | ALDH1A1 (0.41) | SMN1; SMN2ALDH1A1KMT2AMEN1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635587-B1 | 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2017-02-15 | — | — | EP | disclosed |
| EP-2635587-B1 | 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO LTD (CN) | 2017-02-15 | — | — | EP | disclosed |
| US-9540396-B2 | 6-arylamino pyridone carboxamide as MEK inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9540396-B2 | 6-arylamino pyridone carboxamide as MEK inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9540396-B2 | 6-arylamino pyridone carboxamide as MEK inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-10 | — | — | US | disclosed |
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| EP-2635587-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | Centaurus Biopharma Co., Ltd. (CN) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012059041-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012059041-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080804-A1 | NOVEL 6-ARYLAMINO PYRIDONE CARBOXAMIDE AS MEK INHIBITORS | MAP3K6, MAP3K1, MAP3K21 | SMN1; SMN2 2701/4885ALDH1A1 3046/4885KMT2A 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.